Latest Insider Transactions at Heron Therapeutics, Inc. (HRTX)
This section provides a real-time view of insider transactions for Heron Therapeutics, Inc. (HRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HERON THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HERON THERAPEUTICS, INC. 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 13
2023
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+6.12%
|
-
|
|
Jan 13
2023
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-2.85%
|
$15,657
$3.17 P/Share
|
|
Jan 13
2023
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,767
+5.11%
|
-
|
|
Jan 13
2023
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-7.14%
|
$6,036
$3.17 P/Share
|
|
Jan 13
2023
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+9.49%
|
-
|
|
Dec 16
2022
|
Stephen Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+42.58%
|
-
|
|
Dec 16
2022
|
Sharmila Dissanaike Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+41.1%
|
-
|
|
Dec 16
2022
|
Craig A Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+42.65%
|
-
|
|
Dec 16
2022
|
Susan Rodriguez Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+41.1%
|
-
|
|
Dec 16
2022
|
Waage Christian Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+42.48%
|
-
|
|
Oct 31
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Other acquisition or disposition
|
Direct |
1,655
+7.6%
|
$4,965
$3.27 P/Share
|
|
Oct 31
2022
|
Barry D Quart Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,655
+1.0%
|
$4,965
$3.27 P/Share
|
|
Oct 31
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Other acquisition or disposition
|
Direct |
1,654
+6.89%
|
$4,962
$3.27 P/Share
|
|
Oct 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-8.86%
|
$6,036
$3.76 P/Share
|
|
Oct 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+11.59%
|
-
|
|
Oct 13
2022
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-3.13%
|
$15,657
$3.76 P/Share
|
|
Oct 13
2022
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,768
+5.58%
|
-
|
|
Oct 13
2022
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-4.9%
|
$6,036
$3.76 P/Share
|
|
Oct 13
2022
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+6.66%
|
-
|
|
Oct 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
861
-4.01%
|
$2,583
$3.76 P/Share
|
|
Oct 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,485
+5.51%
|
-
|
|
Oct 13
2022
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-9.82%
|
$6,036
$3.76 P/Share
|
|
Oct 13
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+12.75%
|
-
|
|
Jul 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-10.64%
|
$6,036
$3.01 P/Share
|
|
Jul 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+13.73%
|
-
|
|
Jul 13
2022
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-3.42%
|
$15,657
$3.01 P/Share
|
|
Jul 13
2022
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,768
+6.08%
|
-
|
|
Jul 13
2022
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-5.4%
|
$6,036
$3.01 P/Share
|
|
Jul 13
2022
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+7.3%
|
-
|
|
Jul 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
860
-4.34%
|
$2,580
$3.01 P/Share
|
|
Jul 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,485
+5.94%
|
-
|
|
Jul 13
2022
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-12.06%
|
$6,036
$3.01 P/Share
|
|
Jul 13
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+15.41%
|
-
|
|
May 03
2022
|
Kimberly Manhard EVP, Drug Development |
SELL
Open market or private sale
|
Direct |
1,504
-12.15%
|
$6,016
$4.76 P/Share
|
|
Apr 29
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Other acquisition or disposition
|
Direct |
1,505
+10.31%
|
$4,515
$3.84 P/Share
|
|
Apr 29
2022
|
Barry D Quart Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,504
+1.12%
|
$4,512
$3.84 P/Share
|
|
Apr 29
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Other acquisition or disposition
|
Direct |
1,504
+10.84%
|
$4,512
$3.84 P/Share
|
|
Apr 13
2022
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-15.62%
|
$12,072
$6.07 P/Share
|
|
Apr 13
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+19.61%
|
-
|
|
Apr 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
860
-4.73%
|
$5,160
$6.07 P/Share
|
|
Apr 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,484
+6.44%
|
-
|
|
Apr 13
2022
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-6.01%
|
$12,072
$6.07 P/Share
|
|
Apr 13
2022
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+8.08%
|
-
|
|
Apr 13
2022
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-3.83%
|
$31,314
$6.07 P/Share
|
|
Apr 13
2022
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,768
+6.76%
|
-
|
|
Apr 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-14.8%
|
$12,072
$6.07 P/Share
|
|
Apr 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+18.64%
|
-
|
|
Jan 13
2022
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-22.15%
|
$16,096
$8.3 P/Share
|
|
Jan 13
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+27.56%
|
-
|
|
Jan 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
966
-5.79%
|
$7,728
$8.3 P/Share
|